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1. INTRODUCTION {#mgg31105-sec-0005}
===============

Congenital skeletal dysplasia, a complex group of diseases, is characterized by abnormal growth or morphology of the skeleton. According to 2019 edition of the Nosology (Mortier et al., [2019](#mgg31105-bib-0023){ref-type="ref"}), 461 disorders classified within 42 different groups have been described based on radiologic, molecular and biochemical criteria. Currently accepted prevalence has been reported to be 2.3\~7.6 per 10,000 births (Barbosa‐Buck et al., [2012](#mgg31105-bib-0001){ref-type="ref"}; Dighe, Fligner, Cheng, Warren, & Dubinsky, [2008](#mgg31105-bib-0005){ref-type="ref"}; Rasmussen et al., [1996](#mgg31105-bib-0025){ref-type="ref"}; Schramm & Mommsen, [2018](#mgg31105-bib-0026){ref-type="ref"}; Stoll, Dott, Roth, & Alembik, [1989](#mgg31105-bib-0031){ref-type="ref"}). Duarte et al. reviewed 1,663,610 births among 160 hospitals, and estimated the prevalence of osteochondrodysplasia in Argentina was 2.20 per 10,000 births (Duarte et al., [2018](#mgg31105-bib-0006){ref-type="ref"}). Barbosa‐Buck et al. analyzed 1,544,496 births in South America from 2000 to 2007 and reported the birth prevalence was about 3.2 per 10,000. Cui et al. ([2012](#mgg31105-bib-0004){ref-type="ref"}) systematically reviewed congenital skeletal dysplasia reported in Chinese biomedical literature from 1978 to 2012. They found the most frequently reported disorders were Marfan syndrome and osterogenesis imperfecta.

Osteogenesis Imperfecta (OI), one of congenital skeletal dysplasia, is a rare heritable collagen type I metabolism disorder which includes a generalized involvement of connective tissues (Shi et al., [2019a](#mgg31105-bib-0028){ref-type="ref"}). Currently, 20 causative genes with 18 subtypes have been identified including *COL1A1, COL1A2, BMP1, CRTAP, P3H1, PPIB, TMEM38B, SERPINH1, FKBP10, PLOD2, IFITM5, SERPINF1, WNT1, CREB3L1, SP7, SPARC, MBTPS2, P4HB, PLS3* and *SEC24D* (Forlino & Marini, [2016](#mgg31105-bib-0008){ref-type="ref"}; Marini et al., [2017](#mgg31105-bib-0020){ref-type="ref"}). The clinical phenotype is broad and ranges from a mild type to a severe type. Genotype and phenotype relationship is unclear. And then an accurate diagnosis of osteogenesis imperfecta can be challenging due to its rarity and variety of phenotype, especially for fetuses.

Ultrasound evaluations are the most common measurement to detect fetal skeletal abnormality in early pregnancy (Ficara, Syngelaki, Hammami, Akolekar, & Nicolaides, [2019](#mgg31105-bib-0007){ref-type="ref"}; Milks, Hill, & Hosseinzadeh, [2017](#mgg31105-bib-0022){ref-type="ref"}; Timor‐Tritsch, Monteagudo, & Peisner, [1992](#mgg31105-bib-0032){ref-type="ref"}; van Zalen‐Sprock, Brons, van Vugt, van der Harten, & van Geijn, [1997](#mgg31105-bib-0035){ref-type="ref"}). However, overlapping features and phenotypic variability of skeletal dyplasias are limited to differentiate OI and provide a definitive diagnosis via image findings. In addition, phenotypic characteristics of OI do not manifest until later in pregnancy, which undoubtedly increase the difficulty in definite diagnosis (Goncalves & Jeanty, [1994](#mgg31105-bib-0010){ref-type="ref"}; Witters, Moerman, & Fryns, [2008](#mgg31105-bib-0037){ref-type="ref"}).

Next generation sequencing (NGS) has been become an attractive option to elucidate the etiology and uncover disease predisposition. The cost of medical care and turnaround time for prenatal diagnosis are greatly reduced via NGS in clinical prenatal tests (Futema, Plagnol, Whittall, Neil, & Humphries, [2012](#mgg31105-bib-0009){ref-type="ref"}; Greenbaum et al., [2019](#mgg31105-bib-0011){ref-type="ref"}; Huang et al., [2013](#mgg31105-bib-0013){ref-type="ref"}; Lord et al., [2019](#mgg31105-bib-0019){ref-type="ref"}; Shaheen et al., [2015](#mgg31105-bib-0027){ref-type="ref"}; Vandrovcova et al., [2013](#mgg31105-bib-0036){ref-type="ref"}). We reckon that NGS breaks the limitations of traditional techniques in the detection of specific mutations among a large number of candidate genes and enables the clinician to provide accurate genetic counseling and offer feasible testing to family. Currently, we designed the NGS panel to establish an accurate diagnosis of genetic skeletal disorders in utero and applied it in two cases of suspected fetuses in Chinese families.

2. MATERIALS AND METHODS {#mgg31105-sec-0006}
========================

2.1. Editorial policies and ethical considerations {#mgg31105-sec-0007}
--------------------------------------------------

Our study was approved by the Research Ethics Committee of the Chinese PLA General Hospital. Informed consents were obtained from all the participants.

2.2. Patients information {#mgg31105-sec-0008}
-------------------------

After approval of the Research Ethics Committee of the Chinese PLA General Hospital, informed consents and samples were obtained from all the participants.

Two cases were referred to the Department of Obstetrics and Gynecology, Chinese PLA general Hospital for suspected fetal skeletal dysplasia between June 2009 and April 2014. In these two cases, ultrasound findings during the routine fetal anomaly scan showed the varying magnitude of bony abnormalities while two couples were apparently healthy as confirmed by general physical examination. The nonconsanguineous couples expressed strong desire to have a definitive diagnosis. They were given extensive genetic counseling before testing.

Case 1, a 28‐year‐old Chinese Han primigravida carried a fetus with suspected skeletal dysplasia. Her husband was a 30‐year‐old Han man. The amniotic fluid sample was taken by amniocentesis under ultrasound guidance at 18 weeks\' gestation.

Case 2, a 36‐year‐old Chinese Han primigravida carried a fetus with suspected skeletal dysplasia. Her husband was a 39‐year‐old Han man. Amniotic fluid was obtained by amniocentesis under ultrasound guidance at 23 weeks\' gestation.

2.3. Ultrasound scanning {#mgg31105-sec-0009}
------------------------

Ultrasound monitoring was used to confirm prenatal diagnosis. In these two cases, biometric data of the fetal skeleton (including biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC), measurements of all long bones, presence of thoracic narrowing, assessment of skeletal mineralization, presence of fractures and skull shape) as well as the presence of additional abnormalities were collected and analyzed in comparison with normal values.

2.4. Fetal karyotype and genetic analysis {#mgg31105-sec-0010}
-----------------------------------------

Amniotic fluid was obtained by amniocentesis under ultrasound guidance for fetal karyotype and molecular genetic analysis.

Karyotype analysis was performed on cultured amniotic fluid cells. Fetal genomic DNA was extracted from amniotic fluid using a DNA Extraction Kit (TianGen, Beijing, China) according to the manufacturer\'s instructions and stored at −20℃ for further analysis. All couples genomic DNA was extracted from whole blood using a DNA Extraction Kit (TianGen, Beijing, China). After fetal DNA was quantified with Nanodrop 2000 (Thermal Fisher Scientific, DE), 3--5 μg DNA was used for the indexed Illumina libraries according to manufacturer\'s protocol. A final library size of 350--400 bp, including adapter sequences, was selected.

The list of disease genes relevant with neonatal disease in the panel for captured and targeted next‐generation sequencing can be seen in Table [S1](#mgg31105-0001-sup-TableS1){ref-type="supplementary-material"}. In total, the targeted regions of potential disease‐related genes were specifically selected by a gene capture technology using a GenCap Custom Enrichment Kit (MyGenostics, Beijing, China) as described previously.

After sequencing, we retrieved high‐quality reads from raw reads by filtering out low‐quality reads (mapping qualities \< 30, total mapping quality zero reads \< 4, long homo‐polymer run \> 5, approximate read depth \< 5, QUAL \< 50.0, phred‐scaled p‐value using Fisher\'s exact test to detect strand bias \> 10.0), and adaptor sequences using the Solexa QA package and the cutadapt program (<http://code.google.com/p/cutadapt/>, v1.9.1). We used the SOAPaligner program to align the clean read sequences to the human reference genome (UCSC Genome Browser hg19). After removing duplicates with Picard software (v1.119), single‐nucleotide polymorphisms (SNPs) were identified using the SOAPsnp program (<http://soap.genomics.org.cn/soapsnp.html>). Subsequently, reads were realigned to the reference genome using the Burrows--Wheeler alignment program (0.7.12‐r1044), and insertions or deletions (InDels) were detected by HaplotypeCaller of GATK software (<https://software.broadinstitute.org/gatk/>, GATK‐3.5) and filtered by VariantFiltration of GATK software. We annotated the identified SNPs and InDels using the exome‐assistant program. Short read alignment and candidate SNP and InDel validation were performed using MagicViewer. We used the PolyPhen, SIFT, and Provean to evaluate variants to determine pathogenicity. By Sanger sequencing, the coding regions of the mutations were identified and screened in 100 unrelated health controls.

3. RESULTS {#mgg31105-sec-0011}
==========

3.1. Clinical information and ultrasound findings {#mgg31105-sec-0012}
-------------------------------------------------

Ultrasound imaging revealed a normal amount of amniotic fluid and no abnormalities in the brain, heart, liver, or kidneys. But we detected the suspected skeletal malformations. Then we performed prenatal screening as Figure [1](#mgg31105-fig-0001){ref-type="fig"}. Details about suspected fetuses are showed as follows:

![Work flow and clinical features of Case 1 & 2](MGG3-8-e1105-g001){#mgg31105-fig-0001}

Case 1, at 18 weeks\' gestation the fetus was found to be abnormal head shape (HC 15.6 cm; BPD 4.0 cm), narrow thorax, bulging abdomen (AC 11.5 cm), markedly shortening of the limbs (femur length 1.03 cm; Figures [1](#mgg31105-fig-0001){ref-type="fig"}, [2](#mgg31105-fig-0002){ref-type="fig"}).

![Ultrasound images of Cases. Case 1 had abnormal head shape (HC 15.6 cm; BPD 4.0 cm) (a, b), bulging abdomen (AC 11.5 cm) (c), markedly shortening of the limbs (d). Case 2 had BPD 5.6 cm (e), AC 16.56 cm (f) and markedly shortening of the limbs (g)](MGG3-8-e1105-g002){#mgg31105-fig-0002}

Case 2, the 23 week\'s ultrasound scan found the fetus presented micromelia and characterized markedly shortening femora with bowing (femur length 2.51 cm; BPD 5.6 cm; Figures [1](#mgg31105-fig-0001){ref-type="fig"}, [2](#mgg31105-fig-0002){ref-type="fig"}).

3.2. Fetal karyotype and targeted exome sequencing {#mgg31105-sec-0013}
--------------------------------------------------

These suspected fetuses did not involve chromosomal abnormalities and were not exposed to teratogen (eg, thalidomide). After the exclusion of these causes, genetic mutations would be screened out using the NGS panel. We performed targeted exome sequencing of 237 genes related to neonatal disease. Our targeted exome sequencing strategy reached the average sequencing depths of 237 and 219 for these two samples. At least 96.4% of targeted regions were covered. Meanwhile, the average coverage of targeted exons for \>10 reads were 85.4% and \>20 reads 78%. In case 1, a total of 706 variants, including 698 SNVs and 8 Indels were initially identified and 674 variants including 663 SNVs and 11 Indels were disclosed in case 2 (Table [1](#mgg31105-tbl-0001){ref-type="table"}). All the variants were then submitted to bioinformatics analysis.

###### 

Variations identified in two cases

  SNVs/Indels                                       Case 1   Case 2         
  ------------------------------------------------- -------- -------- ----- ----
  Initial variants                                  698      8        663   11
  Excluded synonymous variants remaining variants   335      8        321   11
  Excluded variants found in SNP databases          21       1        15    5
  Found in controls                                 0        0        0     0
  Inheritance mode                                  6        0        6     1
  Phenotype‐related genes                           1        0        1     0
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### 3.2.1. Case 1 {#mgg31105-sec-0014}

Excluded 363 synonymous variants there were 335 non‐synonymous and splicing variants. The amounts were further narrowed down to 21 through filter SNP strategy. We excluded the heterozygous genes from AR and narrowed candidate genes based on the phenotype. Heterozygous mutation *COL1A1* c.3307 G \> A (p. G1103S) was identified as causative for the suspected fetus.

### 3.2.2. Case 2 {#mgg31105-sec-0015}

Six hundred and sixty‐three SNV were identified in the sample. Excluding 342 synonymous variants there were 321 non‐synonymous variants and splicing variants. The amounts were further narrowed down to 15 through filter SNP strategy. We excluded the heterozygous genes from AR and narrowed candidate genes to the heterozygous mutation *COL1A1* c.1706 G \> C (p. G569A) that triggered OI and fit the phenotype.

3.3. Expanded familial validation and sanger sequencing confirmation {#mgg31105-sec-0016}
--------------------------------------------------------------------

We validated results from the trio of fetus, mother and father simultaneously using Sanger sequencing. *COL1A1* same mutations were absent in all the parents (Figures [3](#mgg31105-fig-0003){ref-type="fig"} and [4](#mgg31105-fig-0004){ref-type="fig"}). These two mutations were consistent with the dominant inheritance model. They can lead to the substitution of glycine in the triple helical domain of the alpha‐1 type I collagen and SIFT, PolyPhen and Provean analysis predicted these mutations to be deleterious (Table [2](#mgg31105-tbl-0002){ref-type="table"}). These mutations were conserved across human, rat, mouse, zebrafish, chicken and wolf.

![Results of next generation sequence and sanger sequence. Case 1 had a c.3307 G \> A mutation (a, b). Case 2 had c.1705 G \> C (c, d)](MGG3-8-e1105-g003){#mgg31105-fig-0003}

![Mutation analysis in *COL1A1*. (a) Pedigree of family. (b) Genomic structure of *COL1A1*. Novel mutations had not been detected in parents. Both mutations were identified in domain. (c, d) Sequence chromatogram of affected individual (heterozygous) and control (wild type). (e, f) Conservation analysis showing that these two mutations in *COL1A1* is conserved across human (*homo spains*), wolf (*Canis lupus familiaris*), zebrafish (*Danio rerio*), chicken (*Grallus gallus*), mouse (*Mus musculus*) and rat (*Rattus norvegicus*)](MGG3-8-e1105-g004){#mgg31105-fig-0004}

###### 

Mutations identified in the present study

           Nucleotide     Amino acid   Type       Status   Exon   SIFT          PolyPhen            Provean       Novel
  -------- -------------- ------------ ---------- -------- ------ ------------- ------------------- ------------- -------
  Case 1   c.3307G \> A   p.G1103S     Missense   Het      45     Deleterious   Probably Damaging   Deleterious   Yes
  Case 2   c.1706G \> C   p.G569A      Missense   Het      25     Deleterious   Probably Damaging   Deleterious   Yes
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Moreover, the *COL1A1* c.3307 G \> A and c.1706 G \> C mutations were not reported in the Human Gene Mutation Database, Exome Variant Server (EVS), the 1,000 Genomes databases, or in any other SNP database, and were not found in 100 unrelated control individuals. Taken together, causative mutations are finalized in these two cases via TES and Sanger sequencing. These results provide the definite diagnosis of the suspected fetuses: Osteogenesis Imperfecta (OI). In the meantime, our results indicated the disease‐related gene panels can be applied for clinical use.

4. DISCUSSION {#mgg31105-sec-0017}
=============

NGS has been harnessed as a tool to figure out genetic mutations in a group of disorders which have historically been difficult to diagnose and identify incidental findings, such as novel pathogenic mutations and unexpected diagnoses unrelated to the primary indication for testing (Hordyjewska‐Kowalczyk et al., [2019](#mgg31105-bib-0012){ref-type="ref"}; Kizilors et al., [2019](#mgg31105-bib-0015){ref-type="ref"}; Liu, Zhu, Roberts, & Tong, [2019](#mgg31105-bib-0017){ref-type="ref"}). However, several studies have already demonstrated that exome sequencing can further improve and increase the depth of coverage in gene sequencing (Beauregard‐Lacroix et al., [2019](#mgg31105-bib-0002){ref-type="ref"}; Coutelier et al., [2018](#mgg31105-bib-0003){ref-type="ref"}; Locke et al., [2019](#mgg31105-bib-0018){ref-type="ref"}; Lord et al., [2019](#mgg31105-bib-0019){ref-type="ref"}; Song et al., [2019](#mgg31105-bib-0030){ref-type="ref"}). Here, we described that exome sequencing can provide accurate prenatal diagnosis of fetal osteogenesis imperfecta (OI) company with ultrasound. In fetuses with ultrasound scan abnormalities, the results showed that a single mutation was found in autosomal dominant gene *COL1A1* which may be one of causative genes for OI.

Osteogenesis imperfecta is a generalized disorder of connective tissue which is characterized by fragile bones and easy susceptibility to fracture with clinical and genetical heterogeneity. The prevalence of this disease is about 1/10,000--20,000 births (van Dijk et al., [2011](#mgg31105-bib-0033){ref-type="ref"}; Sillence, Senn, & Danks, [1979](#mgg31105-bib-0029){ref-type="ref"}; Van Dijk & Sillence, [2014](#mgg31105-bib-0034){ref-type="ref"}). Traditionally individuals with OI are classified into four subtypes: type I, MIM \#166200, is the mildest form, which is characterized with blue sclera; type II, MIM \#166210, is pre‐ or perinatally lethal; type III (MIM \#259420), the most severe form, presents progressively deforming; and type IV (MIM \#166220) is the mild to moderate form, intermediate between type I and III. With a deeper understanding of OI, additional OI subtypes and disease‐causing genes have been defined. However, *COL1A1*(OMIM 120150) and *COL1A2*(OMIM 120160) are still the predominant cause of OI.

Mutations in *COL1A1* and *COL1A2* can result in the abnormal type I collagen, which is the major protein component of the extracellular matrix in bone, skin and tendon. Type I collagen consists of two ɑ1 chains (encoded by *COL1A1* gene) and one ɑ2 chain(encoded by *COL1A2).* Mutations in *COL1A1* and *COL1A2* trigger OI as the following ways: one is quantitative defect that a group of variations including frameshift, nonsense, etc. lead to the synthesis of a reduced amount of normal type I collagen; the other is structural defect that missense mutation, mainly involving glycine replacement within Gly‐Xaa‐Yaa repeat, which results in the synthesis of collagen with abnormal structure (Lin et al., [2015](#mgg31105-bib-0016){ref-type="ref"}; Marini et al., [2017](#mgg31105-bib-0020){ref-type="ref"}, [2007](#mgg31105-bib-0021){ref-type="ref"}; Shi et al., [2019a](#mgg31105-bib-0028){ref-type="ref"}). Glycine of the Gly‐Xaa‐Yaa repeat domain occupies the crowded center of the triple helix. The substitution of glycine into other residues will affect the correct formation of collagen, permit prolonged access of modifying enzymes and decrease the thermal stability of the protein (Jia et al., [2017](#mgg31105-bib-0014){ref-type="ref"}; Marini et al., [2007](#mgg31105-bib-0021){ref-type="ref"}; Raghunath, Bruckner, & Steinmann, [1994](#mgg31105-bib-0024){ref-type="ref"}). This is highly conserved in the majority of species. Therefore, mutations on these sites appear to cause OI.

Our study reveals c.1706 G \> C (p. G569A) and c.3307 G \> A (p. G1103S) located in hotspot region of *COL1A1* gene is conserved across human (*homo spains*), wolf (*Canis lupus* familiaris), zebrafish (*Danio rerio*), chicken (*Grallus gallus*), mouse (*Mus musculus*) and rat (*Rattus norvegicus*). SIFT, Polyphen and Provean show that a higher proportion of these two substitutions predict to be deleterious. In addition, we did not find this variant in controls. So we can conclude that these two substitutions may be causative for fetal skeletal dysplasia.

Prenatal diagnosis of skeletal dysplasia depends on ultrasound. Abnormalities in the shape, size and length of the various skeletal elements (relative to gestational week) provide important information for diagnosis. But distinction between OI and other genetic skeletal disorders in a fetus is blurred, which generally has a negative effect on a definite diagnosis. In addition, the absence of a relevant family history increases the difficulty of accurate prenatal diagnosis. The combination of NGS results and ultrasound findings can lead to an experienced clinician to suspect certain candidate genes, eventually leading to precise molecular diagnosis. This is of reference importance for informing parental choice, guiding delivery plans, treatments or utero therapy in pregnancy. This method would become the major trend of prenatal diagnosis. However, many limitations still exist, including cost, infrastructural logistics, strategies for patient selection, and interpretation of genetic datasets, which hamper the routine application of NGS in the clinic. Among all, bioinformatics analysis is more important while presents problematic in genetics datasets of prenatal diagnosis. Therefore, more functional analyses are needed to confirm the pathogenesis of distinct mutations, to gain a clearer insight of the mechanism underlying the selectively clinical phenotypes caused by different mutations.

In conclusion, our findings, *COL1A1* c.1706 G \> C (p. G569A) and c.3307 G \> A (p. G1103S), will broaden the spectrum of osteogenesis imperfecta in Chinese patients. Exome sequencing enhances the accurate diagnosis in utero then can provide appropriate genetic counseling.
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